Market research Study for those living with Immune Thrombocytopenia (ITP) and / or Paroxysmal Nocturnal Hemoglobinuria (PNH)

Exafield ITP Study Leaflet

We are conducting a new Study for those living with Immune Thrombocytopenia (ITP) and / or Paroxysmal Nocturnal Hemoglobinuria (PNH). The purpose of this research is to gain a deeper understanding of your experiences and journey with this condition.
The method of this study will be:

1. 60 Minute Web Assisted Discussion

Who are we looking for?

- 11 participants based within the UK who have been diagnosed either Immune Thrombocyto-penia (ITP) and / or Paroxysmal Nocturnal Hemoglobinuria (PNH).

Why should I take part?

- As a thank you for your time, we will offer you £50.00 which is payable as BACS, Cheque or Ama-zon Voucher.

By sharing with us your experiences, needs and wishes you have a real opportunity to influence healthcare decisions and help guide development of patient support and information materials. All answers provided are to be from your own personal experience and will only be used for in-ternal analysis. These will not be published in any external documents, stimulus or communica-tions.


Please contact Rebecca Crehan for more information:
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  (Please say you have been referred by the ITPSA). Contact Number: 01625 914 770

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia (ADVANCE SC+)

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia (ADVANCE SC+)

argenx BVBA is conducting a phase 3, multicentre, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of efgartigimod (ARGX 113), PH20 administered subcutaneously. This is a specially formulated antibody depletion therapy which is a human IgG Fc fragment that targets and binds to the neonatal Fc receptor (FcRn) to increase IgG clearance and block IgG recycling in the body. IgG antibodies accelerate platelet clearance and destruction, and also interfere with proper platelet production. Eligibility is restricted to adult patients 18 years of age or older who have persistent or chronic ITP and a platelet count lower than 30 x 109/L.

For further information please visit https://clinicaltrials.gov/ct2/show/NCT04812925

If you feel you meet the eligibility criteria please discuss with your clincian.

 

 

UK ITPSC Flyer edited 11.29

PROJECT LIVING WITH IMMUNE THROMBOCYTOPENIA (ITP) - Looking for patients

shutterstock 1500052631

PROJECT LIVING WITH IMMUNE THROMBOCYTOPENIA (ITP)

A Pharmaceutical client is looking for patients who have been diagnosed with immune thrombocytopenia (ITP) and would be willing to take part in a 60-minute 7-day online diary and a 60 minute interview on Microsoft teams.

The purpose of the study is to understand the patient experience living with (ITP) Our clients wants to look into their experiences with the treatment they receive and any challenges they may face due to the treatment.

For taking part you will receive as a token of appreciation of your time of £120

If you or if you know anyone who would be interested in taking part please go to the link the below (or cut and paste it into your browser) which will have the initial questions

https://www.surveymonkey.co.uk/r/SN3WMGG